Reaching new heights in liquid biopsy technology with methylation
Epigenetic changes occur early in tumorigenesis and are highly pervasive across a tumor type. This allows DNA methylation cancer biomarkers to be suitable for early detection and have utility across a range of areas relevant to cancer detection and treatment. The development of more specific drugs selectively targeting mutated epigenetic modifiers will help restrict effects to tumor cells only and decrease potential side effects.1, 2 GuardantINFINITY detects an aggregated methylation signal that can distinguish cancer patients from cancer-free patients, at 91% sensitivity and 97% speciﬁcity across a cohort of lung, breast, and CRC samples (Guardant Health generated data).
Watch our webinar to understand how methylation in liquid biopsy applications can bring novel insights across the continuum of care and accelerate biomarker discovery and patient selection for clinical trials.
Watch our Webinar >